Obinutuzumab

Products

Obinutuzumab is commercially available as a concentrate for the preparation of an infusion solution (Gazyvaro). It has been approved in many countries since 2014.

Structure and properties

Obinutuzumab is a recombinant, monoclonal, and humanized type II antibody against CD20 of the IgG1 isotype. It has a molecular weight of approximately 150 kDa. Obinutuzumab is produced by the glycoengineering process, which gives it higher cytotoxicity.

Effects

Obinutuzumab (ATC L01XC15) is antitumoral and has direct and indirect cytotoxic properties against B lymphocytes. The effects are due to binding to the B lymphocyte antigen CD20. Obinutuzumab has a long half-life of more than 34 days.

Indications

In combination with chlorambucil for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) and additional comorbidities.

Dosage

According to the SmPC. The drug is administered as an intravenous infusion.

Contraindications

  • Hypersensitivity

For complete precautions, see the drug label.

Interactions

There are no known interactions with other drugs.

Adverse effects

The most common potential adverse effects include diarrhea and blood count abnormalities such as neutropenia, thrombocytopenia, and anemia.